Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 162

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 162
---
 the Board through internal consultation and consultation with key stakeholders and shareholders.  Subsequently the candidates will be evaluated to ensure they possess these key characteristics –

 ·a commitment to long-term value creation for our stockholders;    ·an appreciation for stockholder feedback;    ·high personal and professional ethics;    ·a proven record of success;    ·sound business judgment;    ·a strategic vision and leadership experience;    ·knowledge of financial services;    ·having no known history of misconduct or disrepute, especially in public or Corporate office;

The Company does not currently pay any third parties to aid it in identifying director candidates.

All members are independent directors in accordance with the Nasdaq Listing Rules.

 50Table of Contents

Compensation Committee

Our Board of Directors also has a Compensation Committee, which reviews or recommends the compensation arrangements for our management and employees and assists the Board of Directors in reviewing and approving matters such as company benefit and insurance plans, including monitoring the performance thereof. The Compensation Committee has a charter (which is reviewed annually) and is composed of two members: Chee Keong Yap and Muhammad Azrul bin Abdul Hamid. Mr. Muhammad Azrul bin Abdul Hamid serves as chairman of this committee. All members are independent in accordance with the Nasdaq Listing Rules.

The Compensation Committee is responsible for:

 ·evaluating the performance of our Chief Executive Officer in light of our company’s corporate goals and objectives and, based on such evaluation: (i) Reviewing and approving the cash compensation of our Chief Executive Officer, and (ii) Reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans;    ·reviewing and recommending to the Board of Directors the cash compensation of our other executive officers;    ·reviewing and establishing our overall management compensation, philosophy and policy;    ·overseeing and administering our compensation and similar plans;    ·reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;    ·retaining and approving the compensation of any compensation advisors;    ·reviewing and approving our policies and procedures for the grant of equity-based awards;    ·reviewing and recommending to the board of directors the compensation of our directors; and    ·preparing the compensation committee report required by SEC rules, if and when required.